NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Signadori Bio

Signadori Bio

Private
ParisHealthcare & Life Scienceshttps://www.signadoribio.com/

Last Round

Seed

May 6, 2026

Total Funding Raised

$13M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Signadori Bio is a biopharmaceutical company developing a next-generation, off-the-shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

monocyte immunotherapyin vivo immunotherapysolid tumor therapycell engineeringp21 proteinoff-the-shelf therapycancer immunotherapymyeloid cell reprogrammingtumor microenvironmentpreclinical biotechdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Signadori Bio Comps

Public and private peers based on sector, stage, and business model.

Signadori Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Signadori Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 6, 2026
View all Funding Rounds

Key People

Founding team and executive leadership

Selwyn Ho

Chief Executive Officer

Executive Team

Signadori Bio Investors

Notable investors and investment history

Signadori Bio investors
InvestorRounds
Taiho VenturesSeed
Sofinnova PartnersSeed
Invivo PartnersSeed
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 22, 2026

    Grew 75% QoQ from 4 to 7 employees.

  • May 6, 2026

    $13M round with Taiho Ventures and Invivo Partners.

View all signals

Signadori Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Signadori Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Signadori Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range7
Year Founded2025
Last FundingMay 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.